Oncothyreon and Array BioPharma Announce Initiation of Phase 1b Trial of ONT-380 in Combination with TDM-1 in Patients with Metastatic HER2+ Breast Cancer
February 20, 2014 at 08:09 AM EST
Oncothyreon Inc. (NASDAQ: ONTY ) and Array BioPharma Inc. (NASDAQ: ARRY ) today announced the initiation of a Phase 1b trial of ONT-380 (ARRY-380) in combination with Kadcyla (ado-trastuzumab emtansine or TDM-1) in patients with metastatic HER2+ breast cancer. ONT-380 is an orally active, reversible and selective small-molecule